Glucose‐6‐phosphate dehydrogenase deficiency affects more than 400 million people or 8% of the general population of malaria‐endemic nations.1, 2, 3 The enzyme G6PD is required in red blood cells to protect the red blood cells against oxidative challenges.4 Specifically, 8‐aminoquinolines, currently the only class of drugs that can totally cure a patient of Plasmodium vivax, submit red blood cells to oxidative stress in a dose‐dependent way. The gene discussed is G6PD; the disease is hyperinsulinemic hypoglycemia, familial, 4.